loading...| Preferred Name |
Tirofiban |
|
| Synonyms |
TIROFIBAN Tirofiban |
|
| Definitions |
A non-peptide tyrosine derivative, with anticoagulant activity. Upon administration, tirofiban antagonizes fibrinogen binding to the platelet cell surface receptor, glycoprotein (GP) IIb/IIIA complex, one of the two purinergic receptors activated by ADP. This prevents the GP IIb/IIIa receptor complex-mediated activation of adenylyl cyclase. This results in decreased levels of cAMP, interferes with the platelet membrane function and subsequent platelet-platelet interaction, prevents the release of platelet granule constituents and prolongs bleeding time. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C76405 |
|
| CAS_Registry |
144494-65-5 |
|
| CHEBI_ID |
CHEBI:9605 |
|
| Chemical_Formula |
C22H36N2O5S |
|
| code |
C76405 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 |
|
| Contributing_Source |
FDA HemOnc |
|
| DEFINITION |
A non-peptide tyrosine derivative, with anticoagulant activity. Upon administration, tirofiban antagonizes fibrinogen binding to the platelet cell surface receptor, glycoprotein (GP) IIb/IIIA complex, one of the two purinergic receptors activated by ADP. This prevents the GP IIb/IIIa receptor complex-mediated activation of adenylyl cyclase. This results in decreased levels of cAMP, interferes with the platelet membrane function and subsequent platelet-platelet interaction, prevents the release of platelet granule constituents and prolongs bleeding time. |
|
| FDA_UNII_Code |
GGX234SI5H |
|
| FULL_SYN |
TIROFIBAN Tirofiban |
|
| Has_Salt_Form | ||
| label |
Tirofiban |
|
| Legacy Concept Name |
Tirofiban |
|
| Preferred_Name |
Tirofiban |
|
| prefixIRI |
Thesaurus:C76405 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0247025 |
|
| subClassOf |